Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice
Table 2
Effect of chronic elafibranor (elaf) treatment on the inflammatory profiles of HFD mice with steatohepatitis and CKD.
NC-24w
HFD-24w
HFD-elaf
Kidney weight (mg)
356 ± 10
423 ± 9
318 ± 34
triglyceride, TG, mg/dL
57 ± 3.9
299 ± 28
211 ± 14
Hepatic TG levels (mg/g)
98 ± 7
240 ± 18
200 ± 10
fasting glucose (mg/dL)
116 ± 13
243 ± 28
203 ± 9
fasting Insulin (ng/mL)
1.9 ± 0.2
6.9 ± 0.85
5.2 ± 0.8
Homeostasis model assessment-insulin-resistance (HOMA-IR) index
3.8 ± 0.4
28.8 ± 6.4
18.1 ± 1.1
Aspartate aminotransferase (AST, U/L)
40.9 ± 1.6
117.3 ± 20.1
79.5 ± 4.3
Alanine aminotransferase (ALT, U/L)
46.8 ± 10.3
183.2 ± 6.8
104.2 ± 13.7
IL-6, pg/mL
144 ± 18
223 ± 35
168 ± 9
Kidney IL-6 (pg/mg protein)
1.8 ± 0.4
7 ± 0.8
6.2 ± 1.9
TNFα, pg/mL
12 ± 5
40 ± 11
29 ± 8
Renal TNFα (pg/mg protein)
4 ± 0.8
16 ± 2.3
9 ± 1.1
Renal MPO activity (U/g)
8.6 ± 1.5
51 ± 20
31 ± 4
Renal caspase-3 activity (pmol/µg protein)
35 ± 1
90 ± 5
72 ± 3
NC-24w/HFD-24w: mice receiving 24-week high-fat diet (HFD) or normal chow (NC) feeding and vehicle treatment; NC-elaf/HFD-elaf: HFD- or NC-fed mice receiving 12-week elafibranor treatment from to week of either HFD or NC feeding; HOMA-IR: calculated as (fasting glucose×fasting insulin)/58.32. p<0.05,0.01 vs. NC-group; ,p<0.05, 0.01 vs. HFD-group.
